Moderna said its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu shot in adults aged 50 years and older in a late-stage study. Shares of the company were up 2.

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a standard flu shot, the company announced this week.

Moderna (NASDAQ:MRNA), on Monday, reported positive results from a late-stage study comparing its influenza vaccine candidate, mRNA-1010, to a standard vaccine in adults aged 50 and older. The results showed that mRNA-1010 met the highest effectiveness standard set in the study plan,